UK markets closed

Biophytis S.A. (BPTS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4000+0.1300 (+10.24%)
As of 10:33AM EDT. Market open.

Biophytis S.A.

Sorbonne University
BC 9, BAtiment A 4Eme Etage 4 place Jussieu Cedex 05
Paris 75005
France
33 1 44 27 23 00
https://www.biophytis.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees26

Key executives

NameTitlePayExercisedYear born
Mr. Stanislas Veillet Ph.D.Chairman & CEO485.25kN/A1965
Mr. Philippe J. RousseauChief Financial OfficerN/AN/A1971
Mr. Waly DiohChief Operating OfficerN/AN/A1969
Dr. Pierre J. DildaChief Scientific OfficerN/AN/A1970
Mr. Bart Goddyn J.D.Chief Legal Officer & HR DirectorN/AN/AN/A
Dr. Rene LafontScientific Advisor & Member of Scientific Advisory BoardN/AN/A1946
Mr. Benoit CanolleChief Bus. OfficerN/AN/A1978
Mr. Rob van Maanen FFPM, M.B.A., M.D.Chief Medical OfficerN/AN/A1970
Ms. _ TeylanFinancial ControllerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Corporate governance

Biophytis S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.